Paediatric B-Cell non- Hodgkin lymphoma: a single institution experience

Vasiliki Frasandrea-Sidi; Nikolaos Gompakis; Iaonnis Venizelos; Ioanna Fragandrea; Emmanuel Xatzipantelis; Eugenia Papakonstantinou; D Koliouskas; Anna Karakoli; Dimitrios Koliouskas

doi:10.1002/pbc.21342

Abstract

Purpose. The aim of this study is to evaluate the clinical characteristics of the B-cell non Hodgkin Lymphoma (NHL) and therapeutic efficacy of UKCCSG NHL protocol. Methods. From January 1993 to December 2004 32 newly diagnosed children with B-NHL were enrolled. The Murphy classification was used for staging. The patients treated with 901, 902, 903 and HN-97 protocol (UKCCSG-NHL). Results. 32 children (25 boys and 7 girls with a median age of 5,8 years (range:2,5– 15) were treated in our center. There were 3 patients in stage I, 10 in stage II, 14 in stage III and 5 in stage IV. In 17 children the primary tumor was in abdomen, in 8 at the head and neck region, in 2 at the brain, in 2 at peripheral nodal and 3 children had disseminated disease. Burkitt, non Burkitt and anaplastic large cell lymphoma were encountered in: 22 (68,7%) 8 (25%) and 2 (62%) patients respectively. All patients were treated with UKCCSG NHL protocol (3 with 901, 24 with 902, 3 with 903 and 2 with HN-97 protocol). Complete remission occurred in 25 patients (78%), partial remission in 5 (15%) and progressive disease in 2 children (6%) 4 children underwent autologous stem cell transplantation. At a median follow up of 65 (22–126) months the event free survival (EFFS) for all patients was 84,3%. Conclusion. The UKCCSG NHL protocol is very effective for children and adolescents with B cell NHL. More follow up is needed to evaluate long term toxicity.

Original language	English
Pages (from-to)	454
Number of pages	1
Journal	Pediatric Blood and Cancer
Volume	49
Issue number	4
DOIs	https://doi.org/10.1002/pbc.21342
Publication status	Published - 1 Oct 2007
Event	39th Annual Congress of International Society of Paediatric Oncology - Mumbai, India Duration: 31 Oct 2007 → 3 Nov 2007

Keywords

childhood cancer
lymphoma
treatment

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/pbc.21342

Cite this

@article{6a0635ab5b084b3f81ed140935240e3b,

title = "Paediatric B-Cell non- Hodgkin lymphoma: a single institution experience",

abstract = "Purpose. The aim of this study is to evaluate the clinical characteristics of the B-cell non Hodgkin Lymphoma (NHL) and therapeutic efficacy of UKCCSG NHL protocol. Methods. From January 1993 to December 2004 32 newly diagnosed children with B-NHL were enrolled. The Murphy classification was used for staging. The patients treated with 901, 902, 903 and HN-97 protocol (UKCCSG-NHL). Results. 32 children (25 boys and 7 girls with a median age of 5,8 years (range:2,5– 15) were treated in our center. There were 3 patients in stage I, 10 in stage II, 14 in stage III and 5 in stage IV. In 17 children the primary tumor was in abdomen, in 8 at the head and neck region, in 2 at the brain, in 2 at peripheral nodal and 3 children had disseminated disease. Burkitt, non Burkitt and anaplastic large cell lymphoma were encountered in: 22 (68,7%) 8 (25%) and 2 (62%) patients respectively. All patients were treated with UKCCSG NHL protocol (3 with 901, 24 with 902, 3 with 903 and 2 with HN-97 protocol). Complete remission occurred in 25 patients (78%), partial remission in 5 (15%) and progressive disease in 2 children (6%) 4 children underwent autologous stem cell transplantation. At a median follow up of 65 (22–126) months the event free survival (EFFS) for all patients was 84,3%. Conclusion. The UKCCSG NHL protocol is very effective for children and adolescents with B cell NHL. More follow up is needed to evaluate long term toxicity.",

keywords = "childhood cancer, lymphoma, treatment",

author = "Vasiliki Frasandrea-Sidi and Nikolaos Gompakis and Iaonnis Venizelos and Ioanna Fragandrea and Emmanuel Xatzipantelis and Eugenia Papakonstantinou and D Koliouskas and Anna Karakoli and Dimitrios Koliouskas",

year = "2007",

month = oct,

day = "1",

doi = "10.1002/pbc.21342",

language = "English",

volume = "49",

pages = "454",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

number = "4",

note = "39th Annual Congress of International Society of Paediatric Oncology, SIOP 2007 ; Conference date: 31-10-2007 Through 03-11-2007",

}

TY - JOUR

T1 - Paediatric B-Cell non- Hodgkin lymphoma

T2 - 39th Annual Congress of International Society of Paediatric Oncology

AU - Frasandrea-Sidi, Vasiliki

AU - Gompakis, Nikolaos

AU - Venizelos, Iaonnis

AU - Fragandrea, Ioanna

AU - Xatzipantelis, Emmanuel

AU - Papakonstantinou, Eugenia

AU - Koliouskas, D

AU - Karakoli, Anna

AU - Koliouskas, Dimitrios

PY - 2007/10/1

Y1 - 2007/10/1

N2 - Purpose. The aim of this study is to evaluate the clinical characteristics of the B-cell non Hodgkin Lymphoma (NHL) and therapeutic efficacy of UKCCSG NHL protocol. Methods. From January 1993 to December 2004 32 newly diagnosed children with B-NHL were enrolled. The Murphy classification was used for staging. The patients treated with 901, 902, 903 and HN-97 protocol (UKCCSG-NHL). Results. 32 children (25 boys and 7 girls with a median age of 5,8 years (range:2,5– 15) were treated in our center. There were 3 patients in stage I, 10 in stage II, 14 in stage III and 5 in stage IV. In 17 children the primary tumor was in abdomen, in 8 at the head and neck region, in 2 at the brain, in 2 at peripheral nodal and 3 children had disseminated disease. Burkitt, non Burkitt and anaplastic large cell lymphoma were encountered in: 22 (68,7%) 8 (25%) and 2 (62%) patients respectively. All patients were treated with UKCCSG NHL protocol (3 with 901, 24 with 902, 3 with 903 and 2 with HN-97 protocol). Complete remission occurred in 25 patients (78%), partial remission in 5 (15%) and progressive disease in 2 children (6%) 4 children underwent autologous stem cell transplantation. At a median follow up of 65 (22–126) months the event free survival (EFFS) for all patients was 84,3%. Conclusion. The UKCCSG NHL protocol is very effective for children and adolescents with B cell NHL. More follow up is needed to evaluate long term toxicity.

AB - Purpose. The aim of this study is to evaluate the clinical characteristics of the B-cell non Hodgkin Lymphoma (NHL) and therapeutic efficacy of UKCCSG NHL protocol. Methods. From January 1993 to December 2004 32 newly diagnosed children with B-NHL were enrolled. The Murphy classification was used for staging. The patients treated with 901, 902, 903 and HN-97 protocol (UKCCSG-NHL). Results. 32 children (25 boys and 7 girls with a median age of 5,8 years (range:2,5– 15) were treated in our center. There were 3 patients in stage I, 10 in stage II, 14 in stage III and 5 in stage IV. In 17 children the primary tumor was in abdomen, in 8 at the head and neck region, in 2 at the brain, in 2 at peripheral nodal and 3 children had disseminated disease. Burkitt, non Burkitt and anaplastic large cell lymphoma were encountered in: 22 (68,7%) 8 (25%) and 2 (62%) patients respectively. All patients were treated with UKCCSG NHL protocol (3 with 901, 24 with 902, 3 with 903 and 2 with HN-97 protocol). Complete remission occurred in 25 patients (78%), partial remission in 5 (15%) and progressive disease in 2 children (6%) 4 children underwent autologous stem cell transplantation. At a median follow up of 65 (22–126) months the event free survival (EFFS) for all patients was 84,3%. Conclusion. The UKCCSG NHL protocol is very effective for children and adolescents with B cell NHL. More follow up is needed to evaluate long term toxicity.

KW - childhood cancer

KW - lymphoma

KW - treatment

U2 - 10.1002/pbc.21342

DO - 10.1002/pbc.21342

M3 - Conference abstract

SN - 1545-5009

VL - 49

SP - 454

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 4

Y2 - 31 October 2007 through 3 November 2007

ER -